ANI Pharmaceuticals, Inc. and Novitium Pharma LLC to Divest Rights and Assets

Federal Trade Commission (FTC)

WASHINGTON, D.C. — Following a public comment period, the Federal Trade Commission this week approved a final order settling charges that ANI Pharmaceuticals, Inc.’s $210 million acquisition of Novitium Pharma LLC violated federal antitrust laws.

First announced in November 2021, the complaint alleged that the acquisition as proposed likely would have harmed competition in the U.S. markets for generic SMX-TMP oral suspension, an antibiotic used to treat infections, and generic dexamethasone tablets, an oral steroid product used to treat inflammation associated with a variety of conditions.

The final order requires ANI and Novitium to divest ANI’s rights and assets to generic SMX-TMP oral suspension and generic dexamethasone tablets to Prasco LLC within 10 days after the acquisition is final. The final order also contains a prior approval provision that gives the Commission notice and approval rights for future related acquisitions in these markets.

READ:  Federal Trade Commission Sends More than $2 Million to Students Harmed by Debt Relief Scam

The Commission vote to approve the final order was 4-0.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.